XML 117 R30.htm IDEA: XBRL DOCUMENT v3.20.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)
 12 Months Ended
Dec. 31, 2019
Accounting Policies [Abstract]  
Disaggregation of Revenue
The following tables disaggregate our net sales from contracts with customers by Global Business Unit (GBU) between the U.S. and international:
As Restated
201920182017
years ended December 31 (in millions)U.S.InternationalTotalU.S.InternationalTotalU.S.InternationalTotal
Renal Care1
$791  $2,848  $3,639  $816  $2,835  $3,651  $754  $2,737  $3,491  
Medication Delivery2
1,822  977  2,799  1,690  974  2,664  1,698  1,002  2,700  
Pharmaceuticals3
940  1,215  2,155  996  1,091  2,087  892  994  1,886  
Clinical Nutrition4
320  552  872  321  554  875  359  526  885  
Advanced Surgery5
535  342  877  466  332  798  403  305  708  
Acute Therapies6
184  351  535  174  341  515  147  310  457  
Other7
234  251  485  260  249  509  257  200  457  
Total Baxter$4,826  $6,536  $11,362  $4,723  $6,376  $11,099  $4,510  $6,074  $10,584  
1 Renal Care includes sales of our peritoneal dialysis (PD), hemodialysis (HD) and additional dialysis therapies and services.
2 Medication Delivery includes sales of our IV therapies, infusion pumps, administration sets and drug reconstitution devices.
3 Pharmaceuticals includes sales of our premixed and oncology drug platforms, inhaled anesthesia and critical care products and pharmacy compounding services.
4 Clinical Nutrition includes sales of our parenteral nutrition (PN) therapies and related products.
5 Advanced Surgery includes sales of our biological products and medical devices used in surgical procedures for hemostasis, tissue sealing and adhesion prevention.
6 Acute Therapies includes sales of our continuous renal replacement therapies (CRRT) and other organ support therapies focused in the intensive care unit (ICU).
7 Other primarily includes sales of contract manufacturing services from our pharmaceutical partnering business.